f you are a type I or type II diabetic, you may be eligible to participate in a Continuous Glucose Monitoring (CGM) study. The study is NOT intended to change your Diabetes treatment.  It is seeking to continue the development of an experimental CGM system.  You will be asked to wear a CGM for about 14 days with frequent self- glucose monitoring (supplies provided). The results of the CGM will later be compared to your self- glucose monitoring. 

Read more about the study here.

Are you one of the many people who experience moderate to severe migraine headaches at least twice monthly?  If so, We are seeking people like you to participate in a research study for the treatment of migraine headaches.  Participants will help learn more about the safety and effectiveness of an investigational medication.

Click here to learn more. 

We have several studies for people with Type 2 Diabetes who wish to gain better control of their health and lose weight. 

For more information, click here.

If you are struggling with weight management or need to participate in a weight loss program, we are seeking individuals who are ready to make the change.  A change in lifestyle, exercise along with medication.  Our research study combines such.  The purpose of this research study is to compare the safety and effectiveness of a research medication (Long acting human hormone) compared to a placebo.  At the end of the treatment period, all participants will have the opportunity to receive active medication.  Compensation is available for up to $1980 for time and travel.

What is required?

1. Ability to attend monthly clinic visits
2. Willing to give yourself and injection
3. Lifestyle changes as needed (dietary and exercise counseling provided)

Who can participate?

1. 18 years of age and older
2. BMI > 27
3. Committed to lose weight

There are no costs or insurance required.  All related visits, study medications and procedures are free of charge.  For details call our office at 615-329-2222 or click on the link to complete a basic form.  There are no obligations and compensation is available.

Stop Smoking study- Now Enrolling

Have you tried a GLP-1 medication for weight loss but had to stop because of side effects?

If nausea, vomiting, constipation, or diarrhea made you stop the medication, we’d like to hear from you.

We are currently exploring newer medication options that may help support your weight-loss goals with potentially fewer or more manageable side effects.

Upcoming Study! Get on the waiting list

About 10% of the US Adult population has Type 2 diabetes (T2D).  Since Ozempic (semagludtide) was FDA approved in 2017 for the treatment of such, GLP-1 drugs have been increasingly used for glucose control.  Ozempic has since been approved for heart and kidney disease and weight loss.  Wegovy (higher dose semaglutide) was approved for weight loss in 2021.   It is estimated that 6% - 12% of US adults are currently taking GLP1 medication with about 1.3% specifically using Ozempic.

If you have been taking Ozempic or Wegovy and have T2D, you are not alone.  Studies have suggested HbA1c can be further lowered with the combination of other medications.

Study participants are needed who are currently taking Ozempic or Wegovy and have been diagnosed with T2D. The purpose of the study is to evaluate the safety and tolerability of switching Ozempic alone to a combination of Ozempic with another medication. All study medication will be provided and there are no placebos.

What is required?

1. Ability to make 13 office visits
2. Wear a provided Continuous Glucose Monitor (CGM) for the duration of the study
3. Complete provided eye exam
4. Adhere to study requirements
5. Lifestyle changes as needed (counseling provided)

Who can participate?

1. 18 and older who are diagnosed with T2D
2. Currently taking Ozempic or Wegovy
3. Relatively healthy with stable medical and psychiatric conditions
4. Interested in a comprehensive program for improved weight and HbA1C
5. BMI > 25 and HbA1C 6.5- 10.5